Your browser doesn't support javascript.
loading
Agomelatine: a potential novel approach for the treatment of memory disorder in neurodegenerative disease.
Su, Qiang; Li, Tian; Liu, Guo-Wei; Zhang, Yan-Li; Guo, Jun-Hong; Wang, Zhao-Jun; Wu, Mei-Na; Qi, Jin-Shun.
Afiliación
  • Su Q; Key Laboratory of Cellular Physiology, Ministry of Education; Department of Physiology, Shanxi Medical University; Department of Neurology, First Hospital of Shanxi Medical University, Taiyuan, Shanxi Province, China.
  • Li T; Key Laboratory of Cellular Physiology, Ministry of Education; Department of Physiology, Shanxi Medical University, Taiyuan, Shanxi Province, China.
  • Liu GW; Department of Laboratory Medicine, Fenyang College of Shanxi Medical University, Fenyang, Shanxi Province, China.
  • Zhang YL; Department of Neurology, First Hospital of Shanxi Medical University; Department of Neurology, Sixth Hospital of Shanxi Medical University (General Hospital of Tisco), Taiyuan, Shanxi Province, China.
  • Guo JH; Department of Neurology, First Hospital of Shanxi Medical University, Taiyuan, Shanxi Province, China.
  • Wang ZJ; Key Laboratory of Cellular Physiology, Ministry of Education; Department of Physiology, Shanxi Medical University, Taiyuan, Shanxi Province, China.
  • Wu MN; Key Laboratory of Cellular Physiology, Ministry of Education; Department of Physiology, Shanxi Medical University, Taiyuan, Shanxi Province, China.
  • Qi JS; Key Laboratory of Cellular Physiology, Ministry of Education; Department of Physiology, Shanxi Medical University, Taiyuan, Shanxi Province, China.
Neural Regen Res ; 18(4): 727-733, 2023 Apr.
Article en En | MEDLINE | ID: mdl-36204828
Agomelatine is a selective agonist of melatonin receptor 1A/melatonin receptor 1B (MT1/MT2) and antagonist of 5-hydroxytryptamine 2C receptors. It is used clinically to treat major depressive episodes in adults. The pro-chronobiological activity of agomelatine reconstructs sleep-wake rhythms and normalizes circadian disturbances via its agonistic effect of melatonin receptor 1A/melatonin receptor 1B, which work simultaneously to counteract depression and anxiety disorder. Moreover, by antagonizing neocortical postsynaptic 5-hydroxytryptamine 2C receptors, agomelatine enhances the release of dopamine and noradrenaline in the prefrontal cortex, increases the activity of dopamine and noradrenaline, and thereby reduces depression and anxiety disorder. The combination of these two effects means that agomelatine exhibits a unique pharmacological role in the treatment of depression, anxiety, and disturbance of the circadian rhythm. Emotion and sleep are closely related to memory and cognitive function. Memory disorder is defined as any forms of memory abnormality, which is typically evident in a broad range of neurodegenerative diseases, including Alzheimer's disease. Memory impairment and cognitive impairment are common symptoms of neurodegenerative and psychiatric diseases. Therefore, whether agomelatine can improve memory and cognitive behaviors if used for alleviating depression and circadian-rhythm sleep disorders has become a research "hotspot". This review presents the latest findings on the effects of agomelatine in the treatment of psychologic and circadian-rhythm sleep disorders in clinical trials and animal experiments. Our review evaluates recent studies on treatment of memory impairment and cognitive impairment in neurodegenerative and psychiatric diseases.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Neural Regen Res Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: India
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Neural Regen Res Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: India